{Reference Type}: Journal Article
{Title}: Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024.
{Author}: Antunes L;Mazagatos C;Martínez-Baz I;Naesens R;Borg ML;Petrović G;Fatukasi T;Jancoriene L;Machado A;Oroszi B;Husa P;Lazar M;Dürrwald R;Howard J;Melo A;Pérez-Gimeno G;Castilla J;Bernaert E;Džiugytė A;Makarić ZL;Fitzgerald M;Mickienė A;Gomez V;Túri G;Součková L;Marin A;Tolksdorf K;Nicolay N;Rose AMC; ;
{Journal}: Influenza Other Respir Viruses
{Volume}: 18
{Issue}: 8
{Year}: 2024 Aug
{Factor}: 5.606
{DOI}: 10.1111/irv.13360
{Abstract}: We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.